Clinical trial NCT07017348: Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
Official title: Knowledge and Exploratory Study to Better Understand the Gut-Skin Axis in Subjects With Moderate Atopic Dermatitis and Control Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atopic Dermatitis
Healthy
Lead sponsor: Pierre Fabre Dermo Cosmetique
Sponsor class: INDUSTRY
First posted: 2025-06-12
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including joint, cardiovascular, metabolic, or skin diseases, and even mental health.

Many of these effects are attributed to the role of microbiota in controlling intestinal mucosa immunity. For skin diseases, and in particular for Atopic Dermatitis (AD), it has been suggested that the imbalance of the gut microbiome affects systemic inflammation and immune response, which leads to an exacerbation of AD. Complementary to a gut-driven activation of systemic immunity, a role for the nervous system, or even for hormonal pathways can also be envisioned as contributors to the effects of gut microbiome on AD.

Understanding how the gut microbiome controls skin biology, whether it involves or not the immune system, still requires extensive translational research. A better knowledge of the actors and markers of the Gut-Skin axis is therefore necessary to understand the exact mechanisms by which the gut microbiome influences or aggravates AD symptoms.

The study will be conducted in adult subjects, divided into 2 groups:

* Group AD: subjects with moderate atopic dermatitis
* Group CTRL: subjects with no inflammatory dermatological pathology

Number of visits:

2 visits maximum are planned for both groups:

* Visit 1: Inclusion ± end-of-study visit (Day 1)
* Collection phase at home\*: 1 to 5 days (Day 1 to Day 6)
* Visit 2\*\*: End-of-study visit (Day 2 to Day 6) (maximum 24h after faecal sampling at home)

  * If faecal sampling was not possible during the inclusion visit, the kit will be kept by the subject to collect the sample at home.

    * Only if the faecal sampling is carried out at home.

The maximal duration of participation for a subject is 6 days from the inclusion visit to the end of the study.


Eligibility criteria: Inclusion criteria

Criteria related to the population:

* Female
* Subject aged of 18 years old and over
* Subject non-menopausal
* For woman of childbearing potential:

  * use of an effective method of contraception, as assessed by the investigator, introduced and unchanged for at least 1 month before inclusion in the study
  * accept to go on using it during the whole duration of the study

Criteria related to the diseases and/or skin conditions:

Specific for the AD group:

* Subject with atopic dermatitis according to "The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis"
* Subject with moderate atopic dermatitis with a SCORAD between 25 and 40 included
* Subject with target areas on the upper or lower limbs allowing sampling and measurements, defined as:

  * Area of usual atopic dermatitis flare-up with at least one inflammatory flare-up of AD in the year preceding the inclusion visit
  * Area not in actual flare-up but with the following L-SCORAD signs (18-point scale):

    * Erythema score ≥ 1 on a scale ranged from 0 to 3
    * Xerosis score ≥ 1 on a scale ranged from 0 to 3

Specific for the CTRL group:

Subject without inflammatory dermatological conditions (skin and scalp)

Non-inclusion criteria

Criteria related to the population:

* For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study
* Subject having received on target areas artificial UV exposure, excessive or prolonged exposure to natural sunlight within 2 weeks before the inclusion visit
* Subject hirsute on the target areas
* Subject who has shaved or waxed the target areas within the last 2 days before the inclusion visit

Criteria related to the diseases and/or skin conditions:

* Subject having a dermatological condition (excepted AD for atopic dermatitis group), an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the investigator hazardous for the subject or incompatible with the study requirements
* Subject having any other dermatologic condition than atopic dermatitis (for AD group), or characteristics (like tattoo) on the target areas liable to interfere with the study assessments according to the judgement of the investigator
* Subject with intestinal diseases or food allergies liable to interfere with the study, in the opinion of the investigator

Specific for the atopic dermatitis group:

* Subject with a flare-up of AD (requiring a topical or systemic medical treatment in the opinion of the investigator)
* Subject with superinfected AD

Criteria related to treatments and/or products:

* Systemic immunosuppressive treatment (except corticosteroids) taken within 3 months before the inclusion visit or planned during the study
* Systemic antibiotics treatment taken within 4 weeks before the inclusion visit or planned during the study
* Dietary supplements or probiotics taken within 4 weeks before the inclusion visit or planned during the study
* Systemic corticosteroids treatment taken within 4 weeks before the inclusion visit or planned during the study
* Laxative taken within 4 weeks before the inclusion visit or planned during the study
* Phototherapy within 4 weeks before the inclusion visit or planned during the study
* Colonoscopy within 4 weeks before the inclusion visit or planned during the study
* Systemic treatment with NSAID taken in the 7 days prior to the inclusion visit or ongoing at the inclusion visit (from 3 days of intake)
* Topical corticosteroids treatment applied on target areas within 7 days before the inclusion visit or planned during the study
* Topical immunomodulating treatment applied on target areas within 7 days before the inclusion visit or planned during the study
* Topical treatment with NSAID applied on target areas within 7 days before the inclusion visit or planned during the study
* Topical emollient applied on target areas within the last 48h before the inclusion visit
* Any treatment, topical product (excepted emollient) and/or water applied on target areas between the last shower (maximum the evening before inclusion visit) and the inclusion visit

Primary outcomes:
measure: Atopic dermatitis severity on the entire body
timeFrame: baseline (Visit 1- Day 1)
measure: Atopic dermatitis severity on target areas
timeFrame: baseline (Visit 1- Day 1)
measure: Cutaneous pH measurement
timeFrame: baseline (Visit 1- Day 1)
measure: Cutaneous hydration
timeFrame: baseline (Visit 1- Day 1)
measure: Cutaneous barrier integrity
timeFrame: baseline (Visit 1- Day 1)
measure: Microbiota analysis by sampling method with swab by gene sequencing data
timeFrame: baseline (Visit 1- Day 1)
measure: Microbiota analysis by sampling method with feces by gene sequencing data
timeFrame: baseline (Visit 1- Day 1, or Visit 2 - Day 2 to 6)
measure: Metabolites analysis by sampling method with swab by metabolomic technics with mass spectrometry
timeFrame: baseline (Visit 1- Day 1)
measure: Metabolites analysis by sampling method with feces by metabolomic technics with mass spectrometry
timeFrame: baseline (Visit 1- Day 1, or Visit 2 - Day 2 to 6)
measure: Lipids analysis by sampling method with swab by absolute quantification with mass spectrometry
timeFrame: baseline (Visit 1- Day 1)
measure: Proteins analysis by sampling method with feces by metaproteomics workflow with mass spectrometry
timeFrame: baseline (Visit 1- Day 1, or Visit 2 - Day 2 to 6)
measure: Proteins analysis by sampling method with swab by metaproteomics workflow with mass spectrometry
timeFrame: baseline (Visit 1- Day 1)
measure: Digestive health by a questionnaire in both groups on digestive discomfort and abdominal pain
timeFrame: baseline (Visit 1- Day 1)
measure: Dietary habits, health and life by a questionnaire in both groups on diet, consumption of foods, health and lifestyle
timeFrame: baseline (Visit 1- Day 1)
measure: Illustrative photographs of target areas in atopic dermatitis group only
timeFrame: baseline (Visit 1- Day 1)
Secondary outcomes:
Other outcomes:
Locations:
city: Toulouse
country: France
facility: Skin Research Center
Study officials:
References: